Cargando…
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study
BACKGROUND: Cancer clinical trial participation is low and inequitable. Partnering Around Cancer Clinical Trials (PACCT) addressed systemic and interpersonal barriers through an observational study of eligibility and an intervention to improve patient–physician communication and trial invitation rat...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134336/ https://www.ncbi.nlm.nih.gov/pubmed/36540051 http://dx.doi.org/10.1002/cam4.5552 |
_version_ | 1785031741124116480 |
---|---|
author | Eggly, Susan Senft, Nicole Kim, Seongho Heath, Elisabeth I. Jang, Hyejeong Moore, Tanina F. Baidoun, Fatmeh Manning, Mark A. Penner, Louis A. Albrecht, Terrance L. Carducci, Michael A. Lansey, Dina Hamel, Lauren M. |
author_facet | Eggly, Susan Senft, Nicole Kim, Seongho Heath, Elisabeth I. Jang, Hyejeong Moore, Tanina F. Baidoun, Fatmeh Manning, Mark A. Penner, Louis A. Albrecht, Terrance L. Carducci, Michael A. Lansey, Dina Hamel, Lauren M. |
author_sort | Eggly, Susan |
collection | PubMed |
description | BACKGROUND: Cancer clinical trial participation is low and inequitable. Partnering Around Cancer Clinical Trials (PACCT) addressed systemic and interpersonal barriers through an observational study of eligibility and an intervention to improve patient–physician communication and trial invitation rates. METHODS: Physicians at two comprehensive cancer centers and Black and White men with prostate cancer participated. Patients were followed for 2 years to determine whether they became potentially eligible for an available therapeutic trial. Potentially eligible patients were randomized to receive a trials‐focused Question Prompt List or usual care. Patient–physician interactions were video‐recorded. Outcomes included communication quality and trial invitation rates. Descriptive analyses assessed associations between sociodemographic characteristics and eligibility and effects of the intervention on outcomes. RESULTS: Only 44 (22.1%) of participating patients (n = 199) became potentially eligible for an available clinical trial. Patients with higher incomes were more often eligible (>$80,000 vs. <$40,000, adjusted OR = 6.06 [SD, 1.97]; $40,000–$79,000 vs. <$40,000, adjusted OR = 4.40 [SD, 1.81]). Among eligible patients randomized to the intervention (n = 19) or usual care (n = 25), Black patients randomized to the intervention reported participating more actively than usual care patients, while White intervention patients reported participating less actively (difference, 0.41 vs. −0.34). Intervention patients received more trial invitations than usual care patients (73.7% vs. 60.0%); this effect was greater for Black (80.0% vs. 30.0%) than White patients (80.0% vs. 66.7%). CONCLUSIONS: Findings suggest the greatest enrollment barrier is eligibility for an available trial, but a communication intervention can improve communication quality and trial invitation rates, especially for eligible Black patients. |
format | Online Article Text |
id | pubmed-10134336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101343362023-04-28 Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study Eggly, Susan Senft, Nicole Kim, Seongho Heath, Elisabeth I. Jang, Hyejeong Moore, Tanina F. Baidoun, Fatmeh Manning, Mark A. Penner, Louis A. Albrecht, Terrance L. Carducci, Michael A. Lansey, Dina Hamel, Lauren M. Cancer Med RESEARCH ARTICLES BACKGROUND: Cancer clinical trial participation is low and inequitable. Partnering Around Cancer Clinical Trials (PACCT) addressed systemic and interpersonal barriers through an observational study of eligibility and an intervention to improve patient–physician communication and trial invitation rates. METHODS: Physicians at two comprehensive cancer centers and Black and White men with prostate cancer participated. Patients were followed for 2 years to determine whether they became potentially eligible for an available therapeutic trial. Potentially eligible patients were randomized to receive a trials‐focused Question Prompt List or usual care. Patient–physician interactions were video‐recorded. Outcomes included communication quality and trial invitation rates. Descriptive analyses assessed associations between sociodemographic characteristics and eligibility and effects of the intervention on outcomes. RESULTS: Only 44 (22.1%) of participating patients (n = 199) became potentially eligible for an available clinical trial. Patients with higher incomes were more often eligible (>$80,000 vs. <$40,000, adjusted OR = 6.06 [SD, 1.97]; $40,000–$79,000 vs. <$40,000, adjusted OR = 4.40 [SD, 1.81]). Among eligible patients randomized to the intervention (n = 19) or usual care (n = 25), Black patients randomized to the intervention reported participating more actively than usual care patients, while White intervention patients reported participating less actively (difference, 0.41 vs. −0.34). Intervention patients received more trial invitations than usual care patients (73.7% vs. 60.0%); this effect was greater for Black (80.0% vs. 30.0%) than White patients (80.0% vs. 66.7%). CONCLUSIONS: Findings suggest the greatest enrollment barrier is eligibility for an available trial, but a communication intervention can improve communication quality and trial invitation rates, especially for eligible Black patients. John Wiley and Sons Inc. 2022-12-20 /pmc/articles/PMC10134336/ /pubmed/36540051 http://dx.doi.org/10.1002/cam4.5552 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Eggly, Susan Senft, Nicole Kim, Seongho Heath, Elisabeth I. Jang, Hyejeong Moore, Tanina F. Baidoun, Fatmeh Manning, Mark A. Penner, Louis A. Albrecht, Terrance L. Carducci, Michael A. Lansey, Dina Hamel, Lauren M. Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study |
title | Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study |
title_full | Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study |
title_fullStr | Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study |
title_full_unstemmed | Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study |
title_short | Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study |
title_sort | addressing multilevel barriers to clinical trial participation among black and white men with prostate cancer through the pacct study |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134336/ https://www.ncbi.nlm.nih.gov/pubmed/36540051 http://dx.doi.org/10.1002/cam4.5552 |
work_keys_str_mv | AT egglysusan addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT senftnicole addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT kimseongho addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT heathelisabethi addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT janghyejeong addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT mooretaninaf addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT baidounfatmeh addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT manningmarka addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT pennerlouisa addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT albrechtterrancel addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT carduccimichaela addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT lanseydina addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy AT hamellaurenm addressingmultilevelbarrierstoclinicaltrialparticipationamongblackandwhitemenwithprostatecancerthroughthepacctstudy |